abstract |
The present invention relates to methods of treating patients with advanced forms of cancer (e.g., renal clear cell carcinoma) in which X4P-001 is administered to reduce the angiogenic escape that commonly occurs with TKI therapy. These methods show surprising effects, including the regression of tumor size and cell number, and are relatively less toxic. |